Erythromycin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Erythromycin: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Erythromycin is a macrolide antibiotic historically used to treat susceptible bacterial infections (including ophthalmic infections). The TxGNN model predicts it may be effective for Punctate Epithelial Keratoconjunctivitis, but this direction is currently supported only by 2 indirect publications and no dedicated clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (specific TFDA-approved indication text not available in this evidence pack) |
| Predicted New Indication | Punctate Epithelial Keratoconjunctivitis |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding the 50S ribosomal subunit; its efficacy against susceptible Gram-positive (and some Gram-negative) organisms in general bacterial infections is well established.
Punctate epithelial keratoconjunctivitis can arise from bacterial, viral, or other infectious insults to the ocular surface. Mechanistically, an antibacterial agent such as erythromycin could plausibly address a bacterial component of this condition, which is consistent with erythromycin’s established ophthalmic use (e.g., topical ointment for bacterial conjunctivitis and neonatal ophthalmia prophylaxis).
However, the two supporting publications in this evidence pack do not directly evaluate erythromycin’s efficacy in this indication — one is a review of chronic blepharokeratoconjunctivitis management in children, and the other is a case report on molecular diagnosis of microsporidial keratoconjunctivitis. Neither provides direct treatment-outcome evidence for erythromycin in punctate epithelial keratoconjunctivitis specifically.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11495307 | 2001 | Review | Journal of Pediatric Ophthalmology and Strabismus | Describes diagnosis and management of chronic blepharokeratoconjunctivitis in children; general disease-management context, not an erythromycin efficacy study |
| 32826651 | 2021 | Case Report | Cornea | Reports microsporidial (Encephalitozoon hellem) keratoconjunctivitis diagnosed by molecular sequencing; a diagnostic case, not a treatment study |
UK Market Information
No UK marketing authorisations are recorded for this candidate in the current evidence pack (market status: Not marketed; 0 licences on file). This should be verified directly against the MHRA products database and BNF before any further action.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to two indirect publications with no dedicated clinical trials, mechanism-of-action data for the drug is not yet available, and safety labelling data (warnings/contraindications) is a blocking gap that prevents even an initial safety assessment. The drug also has no confirmed UK marketing authorisation to anchor a regulatory pathway.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data from DrugBank or SmPC
- TFDA/MHRA label warnings and contraindications to clear the current blocking safety data gap (DG001)
- Direct clinical evidence (trials or literature) evaluating erythromycin specifically for punctate epithelial keratoconjunctivitis, rather than indirect disease-context publications
- Verification of current UK marketing/licensing status via MHRA
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.